Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of IPF based upon the Fleischner Society guidelines within 3 years from Screening (Part A) or based on ATS/ERS/JRS/ALAT 2018 guidelines within 5 years from Screening (Part B, C \& D)~* FVC % of predicted ≥45%~* DLco (hemoglobin-adjusted) ≥30%~* Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed, if on a stable dose for at least 3 months~Exclusion Criteria:~* Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDA~* Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio \<0.7 at Screening~* Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progression~* Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of Screening~* Smoking of any kind within 3 months of Screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Placebo
- PLN-74809 Dose Level 1 (Part A) (Type: EXPERIMENTAL): PLN-74809 Dose Level 1 (Part A) - 4 weeks
- PLN-74809 Dose Level 2 (Part A) (Type: EXPERIMENTAL): PLN-74809 Dose Level 2 (Part A) - 4 weeks
- PLN-74809 Dose Level 2 (Part B) (Type: EXPERIMENTAL): PLN-74809 Dose Level 2 (Part B) - 12 weeks
- PLN-74809 - Dose Level 3 (Part C) (Type: EXPERIMENTAL): PLN-74809 Dose Level 3 (Part C) - 12 weeks
- PLN-74809 - Dose Level 4 (Part C) (Type: EXPERIMENTAL): PLN-74809 Dose Level 4 (Part C) - 12 weeks
- PLN-74809 - Dose Level 5 (Part D) (Type: EXPERIMENTAL): PLN-74809 Dose Level 5 (Part D) - ≥ 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).